Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (May 2023)
19 slides from Moleculin Biotech's investor presentation, May 12, 2023
Slide 1: Moleculin
ob oc jMOLECULIN
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Investment Highlights
Investment Highlights Annamycin Next generation non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies Portfolio with Focus Annamycin first and foremost. Two additional portfolios (STAT-3 lp rograms for the inhibitors - WP1066 - and anti
Slide 4: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 UPCOMING MILESTONES Phase 1b completed in Q2 2022; Phase 2 dosing started; interim data with quarterly updates .ek Dosing Soft Tissue Sarcoma Lung Mets Commenced Phase 1b/2 study in Poland Q3 022; interim data with quarterl
Slide 5: Additional Development Pipeline
Additional Development Pipeline Additional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 UPCOMING MILESTONES IND/CTA targeted for 2022 for one of these indications — targeting external funding for future Annamycin Liver Mets/Pancreati
Slide 6: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise w NovarTIS ‘MOLECULIN ‘GrowaKirin
Slide 7: Leveraging the Brightest Scientific Minds
Leveraging the Brightest Scientific Minds HEMATOLOGY VIROLOGY Marty Tallman, MD Richard Whitley, MD Memorial Sloan Kettering National inti of o=n ss PANCREATIC James Abbruzzese, MD Jorge Cortes, MD Hongbo Zhai, MD Dana-Farber ‘ae NEW ENGLAND Ceneerinsttte JOURNAL y MEDICINE Wake University EORGIA Sc
Slide 8: Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications Clinical Highlights Demonstrated 60% ORR in Phase 1 in TST; Phase 1b portion commenced Announced RP2D and efficacy of 80% ORR in last cohort of single agent AML trial; Received approval in Italy to conduct Phase 1
Slide 9: Annamycin: Next Generation Anthracycline
Annamycin Next Generation Anthracycline % of Mice with Heart Lesions {a0 weekly VinjetionsZouet al, 1995) 100 Demonstrated to Be Non-Cardiotoxic? Ability to overcome multi-drug resistance Organotrophic properties (e.g. >30x greater accumulation in lungs than doxorubicin) Potent topoisomerase-ll pois
Slide 10: Annamycin: Phase 1b/2 Trial for STS Lung Mets
Annamycin Ongoing Phase 2 Portion of Phase 1b/2 Trial for Treatment of STS Lung Mets U.S. Multi-Center, Open-Label, Dose Escalation Study Demonstrated a Preliminary Response of St Defined as Stable Disease (SD) with STS Lung Mets c 13 of 28 subjects have been 10 subjects have bee dosed two cycles an
Slide 11: Activity of Annamycin in Relapsed or Refractory AML
Activity of Annamycin in Relapsed or a, Refractory (R/R) AML Of the Last 8 Treated Subjects (Combination of MB-105 and MB-106) 4 Had Bone Marrow Blast Percentage Fall to <5% MB-105: Annamycin Monotherapy | Response Rate (ORR) 2D in the Final Cohort tarabine 1 durable CR in First Cohort (n=3) in Ph t
Slide 12: Annamycin: AML Clinical Benefit
Annamycin AML Clinical Benefit? ~\ Patients in Moleculin’s clinical trials taken above the lifetime maximum 32 anthracycline dose established by FDA * Up to 1800 mg/m? in AML study * Up to 1500 mg/m? in STS study (to date) 100% No cardiotoxicity has been ‘0 f fi shown in 42 subjects treated to date
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside 41K a 60K TNBC Lung Pancreatic Liver / 67K RCC Lung 13,500 ‘STS Lung Mets 67K Endometrial Lung Initial Annamycin 20,000 — 104K Target Indications Acute Myeloid Potential Annamycin Colorectal Leukemia a smal Liver TOTAL INCIDENCE Expansi
Slide 14: WP1066: Flagship Immune/Transcription Modulator
WP1066 Flagship Immune/Transcription Modulator Se Expect up to three more externally funded clinically trials in combination with radiation in 2023 in the U.S. and, possibly, in Southeast Asia Received Orphan Drug Designation for the treatment of brain tumors, as well as Rare Pediatric Disease Desig
Slide 15: WP1122 Portfolio
WP1122 Portfolio Metabolism/Glycosylation Inhibitor Key Highlights Prodrug of glucose decoy enables drug-like properties Targets glycolysis and glycosylation; limits viral infectivity and replication Open IND to initiate Phase 1 for treatment of GBM. Clinical Highlights Concluded Phase 1a overlappin
Slide 16: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations Beyond Mid-2024+ 3 Month Avg. Volume? Outstanding*
Slide 17: 2023: The Year of Validating Data
2023: The Year of Validating Data AML AML AML STS(US) — STS (EU) Annamyci o @ e © e Commence dosing Publish CSR MB-106 Phase 2 Phase 1b/2 in Phase 1b/2 Ara-C for MB-105 cohort data interim data interim data combination study Phase 1 results WP1122/ Arenaviruses GBM Pediatric Brain Tumors WP1096/ @ @
Slide 18: Investment Summary
Investment Summary Annamycin Next generation non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies Portfolio with Focus Annamyein first and foremost. Two additional portfolios (STAT-3 inhibitors - WP1066 - and antimetabolites - WP1122)
Slide 19: Thank You
NASDAQ: MBRX | moleculin.com Thank You! 0 db, con MOLECULIN Ops y